Bio Blast Pharma (NASDAQ: ORPN) is one of 294 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Bio Blast Pharma to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends.


This table compares Bio Blast Pharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bio Blast Pharma N/A -155.26% -128.89%
Bio Blast Pharma Competitors -5,449.29% -414.50% -40.60%

Analyst Ratings

This is a summary of current ratings and recommmendations for Bio Blast Pharma and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio Blast Pharma 0 0 1 0 3.00
Bio Blast Pharma Competitors 728 3173 11797 264 2.73

Bio Blast Pharma presently has a consensus target price of $39.08, suggesting a potential upside of 1,668.10%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.24%. Given Bio Blast Pharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Bio Blast Pharma is more favorable than its peers.

Valuation and Earnings

This table compares Bio Blast Pharma and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Bio Blast Pharma N/A -$9.96 million -0.61
Bio Blast Pharma Competitors $473.33 million $171.79 million -7.05

Bio Blast Pharma’s peers have higher revenue and earnings than Bio Blast Pharma. Bio Blast Pharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

9.4% of Bio Blast Pharma shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Bio Blast Pharma has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, Bio Blast Pharma’s peers have a beta of 6.61, indicating that their average share price is 561% more volatile than the S&P 500.


Bio Blast Pharma peers beat Bio Blast Pharma on 7 of the 12 factors compared.

About Bio Blast Pharma

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich’s ataxia) and BBrm-02. The Company’s product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.

Receive News & Stock Ratings for Bio Blast Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd. and related stocks with our FREE daily email newsletter.